Skip to main content
Benefits and Risks of Using AI for Pharmaceutical Development and Delivery
Imagen
WHO. AI for Pharmaceutical Development and Delivery (II)

Author
Gustavo Breitbart (CMO)
Gustavo Breitbart
Chief Medical Officer (CMO)
Publication date

In this post, we introduce the WHO publication, "Benefits and Risks of Using Artificial Intelligence for Pharmaceutical Development and Delivery." This guide covers key concepts such as enhancing the efficiency of drug discovery and improving clinical trials. However, it also addresses risks, including ethical challenges and potential biases in data. Through this document, the WHO emphasizes the need for balance to maximize advantages while mitigating downsides.

As we did with the document "Ethics and Governance of Artificial Intelligence for Health: Guidance on Large Multi-Modal Models," we will publish weekly chapters to aid in its reading and discussion.

Introduction: The Role of Artificial Intelligence in Pharmaceutical Development

The introduction outlines the framework and provides summarized data on AI in the sector. It aims to inform policymakers, researchers, and civil society about the scope and implications of AI in pharmaceutical R&D.

Chapter 1: The Expanding Role of AI in Pharmaceutical R&D

This section covers the various processes involved in R&D:

  • Overview of AI in Pharmaceutical R&D.
  • AI in Basic Scientific Research.
  • Pharmaceutical Discovery and Design.
  • Preclinical Studies and Development.
  • Clinical Trials and Regulatory Approval.
  • Post-Approval Activities.

Chapter 2: Are Commercial Uses of AI Beneficial for Public Health?

While AI has the potential to transform healthcare, its commercial use raises concerns about its benefits for public health and ethical implications. The guide considers these aspects:

  • Precision and Personalized Medicine.
  • Improving Drug Discovery and Clinical Trials.
  • Clinical Trial Recruitment, Adherence, and Marketing.

Conclusion

AI's integration into pharmaceutical R&D is transforming the industry, offering significant advancements in drug discovery, development, and delivery. However, ethical considerations, data privacy, and regulatory oversight remain crucial to ensuring AI's benefits are fully realized while minimizing risks. On the other hand, its commercial use offers significant advancements but also presents ethical challenges and risks to public health. Equitable access, maintaining high R&D standards, and safeguarding patient privacy and safety are essential to maximize its benefits while minimizing its drawbacks.

You can find the complete guide at https://www.who.int/publications/i/item/9789240088108

0
0
Hi! Lets talk!